Protara Therapeutics, INC 10-Q quarterly reports

Protara Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing advancements in its TARA-002 and IV Choline Chloride programs, alongside financial performance and corporate updates.

Protara Therapeutics reports increased R&D spending and a net loss for Q1 2026, while advancing its TARA-002 and IV Choline Chloride programs.

Protara Therapeutics reported an increased net loss in Q3 2025, driven by higher R&D expenses for its clinical programs, while highlighting positive interim data for TARA-002 and progress for IV Choline Chloride.

Protara Therapeutics reported increased net losses in Q2 2025 due to higher research and development expenses, while advancing its TARA-002 and IV Choline Chloride clinical programs.

Protara Therapeutics reports its Q1 2025 financial results, highlighting progress in its clinical programs for TARA-002 and IV Choline Chloride.

Protara Therapeutics reported its financial results for the third quarter of 2024, highlighting progress in its clinical programs for TARA-002 and IV Choline Chloride.

Protara Therapeutics introduces a new equity incentive plan and reports its financial results for the second quarter of 2024, highlighting ongoing clinical trials and financial activities.

Protara Therapeutics reported a net loss of $11.1 million for the first quarter of 2024, while highlighting progress in its clinical programs for TARA-002 and IV Choline Chloride.